加载中
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.
收盘时
US$1.07
−US$0.01 · -0.93%
盘后
US$1.05
−US$0.02 · -1.87%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.
日内区间
当前US$1.07
52周区间
当前US$1.07
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
44
合理估值
情绪
58
多空交织
风险
72
高风险
动量
21
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.
日内区间
当前US$1.07
52周区间
当前US$1.07
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | — | — | 50万 USD | 50万 USD |
| 毛利 | — | — | — | 50万 USD | 50万 USD |
| 研究与开发 | 778.07万 USD | 1163.94万 USD | 1128.77万 USD | 1173.37万 USD | 1061.93万 USD |
| 销售、一般及管理费用 | 687万 USD | 749.3万 USD | 974.27万 USD | 1368.79万 USD | 1088.79万 USD |
| 营业费用 | 1465.07万 USD | 1913.24万 USD | 2103.04万 USD | 2542.16万 USD | 2150.72万 USD |
| 利息收入 | 15.57万 USD | 45.02万 USD | 72.58万 USD | 50.26万 USD | 1.81万 USD |
| 利息支出 | — | — | 19.71万 USD | 502.86万 USD | 56.99万 USD |
| 折旧和摊销 | 69.89万 USD | 71.81万 USD | 72万 USD | 73.16万 USD | 70.29万 USD |
| 营业利润 | −1465.07万 USD | −1913.24万 USD | −2103.04万 USD | −2492.16万 USD | −2100.72万 USD |
| 净利润 | −1449.5万 USD | −1862.02万 USD | −1951.5万 USD | −3589.82万 USD | −2076.93万 USD |
公司数据更新于 2026年10月13日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$10.00
上涨空间 834.58%评级样本有限，仅4项
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
